Myriad Genetics Presents Efficacious MRD Clinical Data
Myriad Genetics, Inc. (NASDAQ: MYGN), a prominent player in molecular diagnostics and precision medicine, recently announced significant results from a study published in The Lancet Oncology. This research delves into the effectiveness of their novel Precise MRD test, specifically in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC).
Objectives and Findings of the Study
Understanding the Goals of the Research
One primary aim of the study was to evaluate the potential benefits of integrating ultrasensitive MRD testing into treatment plans for individuals with oligometastatic ccRCC. The results highlighted that circulating tumor DNA (ctDNA) levels had a significant correlation with patient response to metastasis-directed radiation therapy (MDT). Myriad’s technology effectively identified ctDNA in patients exhibiting minimal tumor burden, thereby opening avenues for tailored treatment options.
Key Insights from the Phase 2 Trial
The study revealed critical insights, including:
- A remarkable 94% of participants exhibited ctDNA levels below 100 ppm at the onset of testing, demonstrating the precision of the technology.
- Participants who tested positive for ctDNA prior to undergoing MDT progressed to requiring systemic therapy within a median period of 27 months, contrasting dramatically with those who tested negative, who were able to continue MDT for an average of 54 months.
- For those with negative ctDNA results maintained on MDT, overall survival remained high, with survival rates reaching 94% at two years and 87% at three years.
Clinical Implications and Future Directions
Impact of the Findings
Dr. Chad Tang, the principal investigator of the study and an associate professor at The University of Texas MD Anderson Cancer Center, expressed that the research illustrates how MDT can effectively postpone the need for systemic therapy in patients diagnosed with oligometastatic ccRCC. He emphasized that median systemic therapy-free survival was nearly twice as long for patients who remained ctDNA negative compared to their ctDNA positive counterparts, indicating the potential of ctDNA as a valuable biomarker for patient management.
Expert Perspectives on Technology
According to Dr. Dale Muzzey, chief scientific officer at Myriad Genetics, the analysis concluded that renal cancer typically presents challenges in ctDNA detection due to low tumor fractions. However, the newly developed Precise MRD Test showcased its capability in detecting a broad spectrum of ctDNA levels, which corresponded with therapeutic responses. This success is promising not only for renal cancer applications but extends to other indications, such as breast cancer, indicating a robust sensitivity profile across various clinical settings.
About Myriad’s Precise MRD Test
The Precise MRD Test by Myriad utilizes tumor-informed, whole genome sequencing (WGS) technology, allowing it to monitor a vast array of tumor-specific variants. This advanced testing provides exceptional sensitivity and quantification of ctDNA present in the blood of cancer patients, enabling continuous monitoring from diagnosis through each phase of treatment.
Myriad Oncology’s Commitment
Myriad Oncology aims to supply comprehensive genetic and genomic testing solutions for oncology specialists and their patients. This includes risk assessment, screening, and facilitating informed treatment decisions, ensuring tailored care that adjusts to the individual needs throughout the entire patient journey.
Frequently Asked Questions
What was the main focus of the study published by Myriad Genetics?
The study focused on evaluating the effectiveness of the Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC)
What are ctDNA levels and why are they significant?
Circulating tumor DNA (ctDNA) levels are important biomarkers that correlate with cancer progression and response to treatment, aiding in personalized therapy approaches.
How does the Precise MRD Test benefit patients?
It provides sensitive detection of ctDNA, allowing for more accurate monitoring of cancer progression and potentially enabling patients to avoid systemic treatments that carry serious side effects.
What outcomes did the Phase 2 trial demonstrate?
Key outcomes included prolonged systemic therapy-free survival for ctDNA negative patients, indicating the test's ability to optimize treatment strategies.
How does this study influence future cancer therapies?
The findings suggest that integrating MRD testing can significantly enhance personalized treatment plans, paving the way for improved patient outcomes in various cancer types.
